Search research articles
Contact Us
Filters
Showing results (81-90 of 91) with videos related to
Page
of 10
Sort By:
British Journal of Cancer
|
October 11, 2025
Modeling response to the KRAS-G12C inhibitor AZD4625 in KRAS<sup>G12C</sup> NSCLC patient-derived xenografts reveals insights into primary resistance mechanisms
Joshua C Rosen, Pinjiang Cao, Nhu-An Pham, et al.
Communications Biology
|
November 2, 2021
Antisense oligonucleotide activity in tumour cells is influenced by intracellular LBPA distribution and extracellular vesicle recycling
Alexander N Kapustin, Paul Davey, David Longmire, et al.
Plos One
|
January 10, 2014
Prevalence and causes of prescribing errors: the PRescribing Outcomes for Trainee Doctors Engaged in Clinical Training (PROTECT) study
Cristín Ryan, Sarah Ross, Peter Davey, et al.
Molecular Cancer Therapeutics
|
June 9, 2012
MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo
David W Jenkins, Sarah Ross, Margaret Veldman-Jones, et al.
Molecular Cancer Therapeutics
|
October 24, 2022
Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer
Hajrah Khawaja, Rebecca Briggs, Cheryl H Latimer, et al.
Molecular Cancer Therapeutics
|
August 5, 2022
AZD4625 is a Potent and Selective Inhibitor of KRASG12C
Atanu Chakraborty, Lyndsey Hanson, David Robinson, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology
|
September 27, 2022
DNA sensor-associated type I interferon signaling is increased in ulcerative colitis and induces JAK-dependent inflammatory cell death in colonic organoids
Peter Flood, Aine Fanning, Jerzy A Woznicki, et al.
Blood
|
June 2, 2021
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity
Antonio Sacco, Cinzia Federico, Katia Todoerti, et al.
Journal of Medicinal Chemistry
|
February 6, 2020
Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRAS<sup>G12C</sup>
Jason G Kettle, Sharan K Bagal, Sue Bickerton, et al.
Journal of Medicinal Chemistry
|
April 26, 2022
Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRAS<sup>G12C</sup>
Jason G Kettle, Sharan K Bagal, Sue Bickerton, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 91) with videos related to
Sort By:
Page
of 10
British Journal of Cancer
|
October 11, 2025
Modeling response to the KRAS-G12C inhibitor AZD4625 in KRAS<sup>G12C</sup> NSCLC patient-derived xenografts reveals insights into primary resistance mechanisms
Joshua C Rosen, Pinjiang Cao, Nhu-An Pham, et al.
Communications Biology
|
November 2, 2021
Antisense oligonucleotide activity in tumour cells is influenced by intracellular LBPA distribution and extracellular vesicle recycling
Alexander N Kapustin, Paul Davey, David Longmire, et al.
Plos One
|
January 10, 2014
Prevalence and causes of prescribing errors: the PRescribing Outcomes for Trainee Doctors Engaged in Clinical Training (PROTECT) study
Cristín Ryan, Sarah Ross, Peter Davey, et al.
Molecular Cancer Therapeutics
|
June 9, 2012
MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo
David W Jenkins, Sarah Ross, Margaret Veldman-Jones, et al.
Molecular Cancer Therapeutics
|
October 24, 2022
Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer
Hajrah Khawaja, Rebecca Briggs, Cheryl H Latimer, et al.
Molecular Cancer Therapeutics
|
August 5, 2022
AZD4625 is a Potent and Selective Inhibitor of KRASG12C
Atanu Chakraborty, Lyndsey Hanson, David Robinson, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology
|
September 27, 2022
DNA sensor-associated type I interferon signaling is increased in ulcerative colitis and induces JAK-dependent inflammatory cell death in colonic organoids
Peter Flood, Aine Fanning, Jerzy A Woznicki, et al.
Blood
|
June 2, 2021
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity
Antonio Sacco, Cinzia Federico, Katia Todoerti, et al.
Journal of Medicinal Chemistry
|
February 6, 2020
Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRAS<sup>G12C</sup>
Jason G Kettle, Sharan K Bagal, Sue Bickerton, et al.
Journal of Medicinal Chemistry
|
April 26, 2022
Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRAS<sup>G12C</sup>
Jason G Kettle, Sharan K Bagal, Sue Bickerton, et al.
Page
of 10